Showing 981-990 of 1110 results for "".
- New Chair, Members Named to Eversight Board of Directorshttps://modernod.com/news/new-chair-members-named-to-eversight-board-of-directors/2477217/Eversight announced that two new members and a new chair have been named to its Board of Directors, effective Jan. 1, 2020. Joining the Eversight Board of Directors are Carolyn Welsh, Vice President & Chief Clinical Officer, NJ Sharing Network; and Mahmoud N. Ghazzi, MD, PhD, MPH, an e
- Largest Study of Chinese Americans Uncovers Unique Risk Factors for Visual Impairmenthttps://modernod.com/news/largest-study-of-chinese-americans-uncovers-unique-risk-factors-for-visual-impairment/2477019/CHA Hollywood Presbyterian Medical Center (CHA HPMC) announced publication of a study by Rohit Varma, MD, MPH, director of its Southern California Eye Institute, assessing risk factors for vision impairment in Chinese Americans. The largest study on Chinese Americans to date, “Factors Associated
- Regenxbio Announces Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476995/Regenxbio announced interim data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). The results were presented by Jeffrey S. Heier, MD, Co-President and Director of Retina Research at Ophthalmic Consultants
- Eyevensys Presents Initial Data from Phase 1/2 Trial of Non-Viral Gene Therapy for Ocular Diseaseshttps://modernod.com/news/eyevensys-presents-initial-data-from-phase-1-2-trial-of-non-viral-gene-therapy-for-ocular-diseases/2476987/Eyevensys this week presented results from part 1 of its phase 1/2 study for noninfectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the nov
- Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Franciscohttps://modernod.com/news/oxurion-nv-to-provide-business-and-clinical-update-at-aao-and-ois-meetings-in-san-francisco/2476969/Oxurion NV announces that the company will be providing a business and clinical update at the American Academy of Ophthalmology’s annual meeting (AAO) and Ophthalmology Innovation Summit (OIS@AAO) in San Francisco. Patrik De Haes, MD, CEO of Oxurion will be presenting the company’s b
- MicroSurgical Technology Releases MST 19-Gauge Ahmed Micro Stent Cutterhttps://modernod.com/news/microsurgical-technology-releases-mst-19-gauge-ahmed-micro-stent-cutter/2476768/To address challenging microstent revision surgery, MicroSurgical Technology (MST), in collaboration with glaucoma and cataract surgeon Ike Ahmed, MD, has developed the MST 19-gauge Ahmed Micro Stent Cutter. Bringing precision and control, the new instrument enables an efficient and minimally inv
- Eye Specialist Works to Prevent Motor Vehicle Related Traumatic Eye Injurieshttps://modernod.com/news/eye-specialist-works-to-prevent-motor-vehicle-related-traumatic-eye-injuries/2476751/Within a 6-week period, Grady Memorial Hospital eye specialist Yousuf Khalifa, MD, witnessed an unusual set of traumatic eye injuries. Three patients, all riding with their windows down, suffered serious eye injuries when the glass in their exterior rear-facing side
- Prism Vision Group Announces Launch of New Brandhttps://modernod.com/news/prism-vision-group-announces-launch-of-new-brand/2476726/Prism Vision Group, an ophthalmology administrative services care provider organization, was officially launched. The new entity is led by Steven Madreperla, MD, PhD, a practicing ophthalmologist and one of the founding partners of NJRetina, a specialty retina practice with roots that reac
- Allegro Announces Positive Results of Ex-US Proof-of-Concept Trial With ALG-1007 for Dry Eye Diseasehttps://modernod.com/news/allegro-ophthalmics-announces-positive-results-of-ex-us-proof-of-concept-trial-with-integrin-inhibitor-alg-1007-for-dry-eye-disease/2476583/Allegro Ophthalmics announced positive results of an ex-US proof-of-concept clinical trial of the new investigational ALG-1007 topical drop drug candidate in patients with dry eye disease (DED). The results were presented by Eric D. Donnenfeld, MD, last week at the 2019 American Society of Catara
- Jefferson and Wills Eye Launch World’s First Center Focused on Connections Between the Eye and the Brainhttps://modernod.com/news/jefferson-and-wills-eye-launch-worlds-first-center-focused-on-connections-between-the-eye-and-the-brain/2476574/Thomas Jefferson University, in partnership with Wills Eye Hospital and thanks to the generosity of several prescient philanthropists, has launched the world’s first center focused on the visual signatures of neurological diseases. The William H. Annesley, Jr., MD ’48 EyeBrain Center will explore